» Articles » PMID: 36672447

Differentiation of Urothelial Carcinoma and Normal Bladder Tissues by Means of Fiber-Based ATR IR Spectroscopy

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Jan 21
PMID 36672447
Authors
Affiliations
Soon will be listed here.
Abstract

Surgical treatment is widely applied curative approach for bladder cancer. White light cystoscopy (WLC) is currently used for intraoperative diagnostics of malignant lesions but has relatively high false-negative rate. Here we represent an application of label free fiber-based attenuated total reflection infrared spectroscopy (ATR IR) for freshly resected human bladder tissue examination for 54 patients. Defined molecular spectral markers allow to identify normal and urothelial carcinoma tissues. While methods of statistical analysis (Hierarchical cluster analysis (HCA) and Principal component analysis (PCA)) used for spectral data treatment allow to discriminate tissue types with 91% sensitivity and 96-98% specificity. In the present study the described method was applied for tissue examination under ex vivo conditions. However, after method validation the equipment could be translated from laboratory studies to in situ or even in vivo studies in operating room.

References
1.
Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

2.
Bannasch P . Sequential cellular changes during chemical carcinogenesis. J Cancer Res Clin Oncol. 1984; 108(1):11-22. DOI: 10.1007/BF00390968. View

3.
Mowatt G, Ndow J, Vale L, Nabi G, Boachie C, Cook J . Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care. 2011; 27(1):3-10. DOI: 10.1017/S0266462310001364. View

4.
Nagaya T, Nakamura Y, Choyke P, Kobayashi H . Fluorescence-Guided Surgery. Front Oncol. 2018; 7:314. PMC: 5743791. DOI: 10.3389/fonc.2017.00314. View

5.
Grossman H, Soloway M, Messing E, Katz G, Stein B, Kassabian V . Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006; 295(3):299-305. DOI: 10.1001/jama.295.3.299. View